Hi Kerrybrad,
It appears the FDA rejected approval due to 2 points.
1) Proof of efficacy using a small, open-label, uncontrolled trial. The fact that the controlled C19 ARDS trial got nowhere near the efficacy of the open-label EAP would tend to support the FDA view.
2) The FDA had concerns surrounding the MOA and the manufacturing process of the cells. My take was they don't believe MSB truly knows precisely how the cells work.
If MSB don't know how they work, how can the biomarkers used to measure batch to batch potency be relied upon?
- Forums
- ASX - By Stock
- MSB
- USD573M in retained losses and a less than great 2020!. 2021 a year that cannot get worse
USD573M in retained losses and a less than great 2020!. 2021 a year that cannot get worse, page-288
-
- There are more pages in this discussion • 24 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
(20min delay)
|
|||||
Last
96.0¢ |
Change
0.025(2.67%) |
Mkt cap ! $1.096B |
Open | High | Low | Value | Volume |
95.0¢ | 96.5¢ | 94.0¢ | $1.231M | 1.291M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
4 | 94461 | 95.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
96.0¢ | 61151 | 6 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
4 | 94461 | 0.950 |
6 | 59977 | 0.945 |
9 | 154571 | 0.940 |
4 | 44875 | 0.935 |
5 | 92633 | 0.930 |
Price($) | Vol. | No. |
---|---|---|
0.960 | 61151 | 6 |
0.965 | 46785 | 5 |
0.970 | 48228 | 6 |
0.975 | 64461 | 2 |
0.980 | 31269 | 3 |
Last trade - 16.10pm 12/09/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |